Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8437163 | 0.79 | KCNH2 (0.42) | SIGMAR1 | |
| SCHEMBL8440881 | 0.79 | SIGMAR1 (0.57) | SIGMAR1NOS1MEN1KMT2ATDP1 | |
| SCHEMBL7658856 | 0.77 | SIGMAR1 (0.69) | SIGMAR1ALDH1A1 | |
| SCHEMBL8440690 | 0.73 | ALDH1A1 (0.56) | ALDH1A1KMT2AHSD17B10KDM4EGAA | |
| SCHEMBL20038521 | 0.73 | CHRNB2 (0.66) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL14314275 | 0.71 | L3MBTL1 (0.55) | NOS1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19847120 | 0.71 | NOS1 (0.42) | SIGMAR1NOS1ALDH1A1MEN1KMT2A | |
| SCHEMBL24322436 | 0.71 | SIGMAR1 (0.50) | SIGMAR1NOS1ALDH1A1MEN1KMT2A | |
| SCHEMBL3320391 | 0.68 | HRH3 (0.44) | SIGMAR1ALDH1A1 | |
| SCHEMBL3920342 | 0.68 | LMNA (0.61) | SIGMAR1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | SIGMAR1 831/4885NOS1 1814/4885ALDH1A1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.